The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
An other investor has been in touch with the CEO this morning - as indicated, OHI was a requirement in order to facilitate bigger deals in India. He expects that ultimately OHI should bring in sales of £10-20m pa.
I wish he would do interviews on the back of these releases, company PR is slack.
There has been a heavy seller here since the jump in gold last week. Compare with GDX it's quite a drop, should be 50/51p still.
Lol this cromwell guy pops in from time to time off the SBTX board. Clueless about Opti but sl@gs it off anyway and tries to ramp his own holding in SBTX. He thinks SBTX is currently undervalued (it isn't). Sounds like he's about 16.
OptiBiotix's partner Sacco has signed an agreement with Dohler for a plant based ingredient mix containing probiotics. This will include LPLDL with Dohler ($>2bn, 7,000 employees) promoting the product on a global scale
Reported for spamming you absolute clown
Valuation – In our recent report (9 September 21) we laid out a three-part valuation analysis pointing to over 200% upside in OptiBiotix shares. This analysis highlighted what we believe is a significant undervaluation of the potential of the second-generation platform, in particular, we believe upside can also be delivered by the first-generation platform.
No evidence to suport this
Totally ignored by the market but watch the presentation at 1:12 where he talks about what they've acheived. They've just managed to perfect the process for engineering a prebiotic to change any gut microbe at an industrial scale, using a unique and patented process. The possibilities for using this to treat disease open up a whole new side of the business. If they are able to use this platform to develop a pharma product then that's when it goes into big numbers. (see 4D for example)
Out today... 'Our valuation analysis suggests the market is attributing little value to the company’s second-generation platform leading us to conclude that there is significant upside in OptiBiotix shares. We maintain our Buy recommendation. '
And 'Combining our three-part valuation analysis, we estimate OptiBiotix is currently offering c225% upside to the current share price, largely based upon a significant undervaluation of the potential of the second-generation platform but also supported by upside from the first-generation platform. '
Might have that by month end if Sprott doesn't relent :-D
Calm down, your trade is here https://www.lse.co.uk/SharePrice.asp?shareprice=OPTI.GB.PL&share=Optibiotix-Health-Plc